Wednesday, July 8, 2026

pharma · MAC Lung Disease · Mycobacterium Abscessus Infection · ANTX

AN2 Therapeutics

AN2 Therapeutics is a pharma organization headquartered in Menlo Park, USA. It trades on NYSE under ticker ANTX. Primary therapeutic focus areas include MAC Lung Disease, Mycobacterium Abscessus Infection, Renal Insuffic

Menlo Park, USA HQ
2019 Founded
35 Employees
Public company Type
ANTX · NYSE Ticker
Company details
Status
Public
HQ
Menlo Park, USA
Founded
2019
Employees
35
Programs
6
Drugs
2
Patents
0
Clinical program

Epetraborole and matching placebo

Phase 1 · small molecule · Healthy Volunteers

Epetraborole and matching placebo for Healthy Volunteers is a Phase 1 program (small_molecule) at AN2 Therapeutics with 1 ClinicalTrials.gov record(s).

← All AN2 Therapeutics projects Phase 1 small molecule completed

Internal code EBO-104

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AN2 Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1